The Latest: CureVac begins phase 3 study of possible vaccine
BERLIN — German pharmaceutical company CureVac says it has enrolled the first participant in the phase 3 clinical study of its mRNA-based COVID-19 vaccine candidate. The Tuebingen-based company says the study is expected to include more than 35,000 participants at sites in Europe and Latin America.
Become a Subscriber!
You have read all of your free articles this month. Select a plan below to start your subscription today.
Already a subscriber? Login
